A review of recent developments on micro/nanostructured pharmaceutical systems for intravesical therapy of the bladder cancer

References

• Alai MS, Lin WJ, Pingale SS. 2015. Application of polymeric nanoparticles and micelles in insulin oral delivery. J Food Drug Anal. 23:351–358.
   PubMed Web of Science ®Google Scholar
• Almeida AE, Souza ALR, Cassimiro DL, Gremião MPD, Ribeiro CA, Crespi MS. 2012. Thermal characterization of solid lipid nanoparticles containing praziquantel. J Therm Anal Calorim. 108:333–339.
   Web of Science ®Google Scholar
• Alva A, Daignault S, Smith DC, Hussain M. 2014. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma. Invest New Drugs. 32:188–194.
   PubMed Web of Science ®Google Scholar
• American Cancer Society’s. Bladder Cancer. 2015. Available from: http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-key-statistics
   Google Scholar
• Amparo RAD. 2013. Avaliação do efeito da Mitomicina C em células uroteliais da bexiga [dissertation]. Portugal (PT): Universidade Fernando Pessoa.
   Google Scholar
• Ansary RH, Awang MB, Rahman MM. 2014. Biodegradable poly(d, l-lactic-co-glycolic acid)-based micro/nanoparticles for sustained release of protein drugs – a review. Trop J Pharm Res. 13:1179–1190.
   Web of Science ®Google Scholar
• Artioli GG, Hirata RDC, Lancha Júnior AH. 2007. Terapia gênica, doping genético e esporte: fundamentação e implicações para o futuro. Rev Bras Med Esporte. 13:349–354.
   Google Scholar
• Azevêdo ES. 1990. Terapia gênica. Rev Bioét. 5:1–11.
   Google Scholar
• Balayssac D, Authier N, Cayre A, Coudore F. 2005. Does inhibition of P-glycoprotein lead to drug–drug interactions? Toxicol Lett. 56:319–329.
   Google Scholar
• Barthelmes J, Perera G, Hombach J, Dünnhaupt S, Bernkop-Schnürch A. 2011. Development of a mucoadhesive nanoparticulate drug delivery system for a targeted drug release in the bladder. Int J Pharm. 416:339–345.
   PubMed Web of Science ®Google Scholar
• Bilensoy E, Sarisozen C, Esendağli G, Doğan AL, Aktaş Y, Şen M, Mungan NA. 2009. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors. Int J Pharm. 371:170–176.
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV, Pardee AB. 2001. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res. 61:4301–4305.
   PubMed Web of Science ®Google Scholar
• Bogataj M, Vovk T, Kerec M, Dimnik A, Grabnar I, Mrhar A. 2003. The correlation between zeta potential and mucoadhesion strength on pig vesical mucosa. Biol Pharm Bull. 26:743–746.
   PubMed Web of Science ®Google Scholar
• Brasil. 2004. Ministério da Saúde. Secretaria de Atenção à Saúde. Instituto Nacional de Câncer. Classificação de Tumores Malignos. Brasil: Rio de Janeiro. Available from: http://www1.inca.gov.br/tratamento/tnm/index.asp
   Google Scholar
• Bruschi ML. 2015. Strategies to modify the drug release from pharmaceutical systems. London: Woodhead Publishing – Elsevier; p. 208.
   Google Scholar
• Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, et al. 2013. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 63:234–241.
   PubMed Web of Science ®Google Scholar
• Calixto G, Bernegossi J, Fonseca-Santos B, Chorilli M. 2014. Nanotechnology-based drug delivery systems for treatment of oral cancer: a review. Int J Nanomedicine. 9:3719–3735.
   PubMed Web of Science ®Google Scholar
• Cao X, Tao L, Wen S, Hou W, Shi X. 2014. Hyaluronic acid-modified multiwalled carbon nanotubes for targeted delivery of doxorubicin into cancer cells. Carbohydr Res. 405:70–77.
   PubMed Web of Science ®Google Scholar
• Castiglioni S, Cazzaniga A, Perrotta C, Maier JA. 2015. Silver nanoparticles-induced cytotoxicity requires Erk activation in human bladder carcinoma cells. Toxicol Lett. 237:237–243.
   PubMed Web of Science ®Google Scholar
• Chang LC, Wu SC, Tsai JW, Yu TJ, Tsai TR. 2009. Optimization of epirubicin nanoparticles using experimental design for enhanced intravesical drug delivery. Pharm Nanotechnol. 376:195–203.
   Google Scholar
• Cheang T-Y, Wang S-M, Hu Z-J, Xing Z-H, Chang G-Q, Yao C, Liu Y, Zhang H, Xu A-W. 2010. Calcium carbonate/CaIP6 nanocomposite particles as gene delivery vehicles for human vascular smooth muscle cells. J Mater Chem. 20:8050–8055.
   Web of Science ®Google Scholar
• Chen CH, Wu Y-J, Chen J-J. 2015. Gold nanotheranostics: photothermal therapy and imaging of mucin 7 conjugated antibody nanoparticles for urothelial cancer. BioMed Res Int. 2015:813632.
   PubMed Web of Science ®Google Scholar
• Chen G, He Y, Wu X, Zhang Y, Luo C, Jing P. 2012. In vitro and in vivo studies of pirarubicin-loaded SWNT for the treatment of bladder cancer. Braz J Med Biol Res. 45:771–776.
   PubMed Web of Science ®Google Scholar
• Chen Z, Yu T, Zhou B, Wei J, Fang Y, Lu J, Guo L, Chen W, Liu Z-P, Luo J, et al. 2016. Mg(II)-catechin nanoparticles delivering siRNA targeting EIF5A2 inhibit bladder cancer cell growth in vitro and in vivo. Biomaterials. 81:125–134.
   PubMed Web of Science ®Google Scholar
• Chou R, Dana T. 2010. Screening adults for bladder cancer: a review of the evidence for the U.S. preventive services task force. Ann Intern Med. 153:461–468.
   PubMed Web of Science ®Google Scholar
• Couvreur P, Vauthier C. 2006. Nanotechnology: intelligent design to treat complex disease. Pharm Res. 23:1417–1450.
   PubMed Web of Science ®Google Scholar
• Cross W, Whelan P. 2010. Bladder cancer. Surgery (Oxford). 28:599–604.
   Google Scholar
• Da Hora Machado AE. 2000. Terapia fotodinâmica: princípios, potencial de aplicação e perspectivas. Quím Nova. 23:237–243.
   Google Scholar
• Daneshmand S. 2016. Safety and tolerability of GemRIS 225 mg in subjects with muscle-invasive bladder cancer. Available from: https://clinicaltrials.gov
   Google Scholar
• De Andrade e Silva UV, Viana LS, de Oliveira e Castro PT, Almeida RDS, da Silva RSP. 2011. Sepse fatal após instilação intravesical de BCG: relato de caso. Rev Bras Ter Intensiva. 23:104–107.
   PubMedGoogle Scholar
• De Souza ALR, Kiill CP, dos Santos FK, da Luz GM, Rocha e Silva H, Chorilli M, Gremiao MPD. 2012. Nanotechnology-based drug delivery systems for dermatomycosis treatment. CNANO. 8:512–519.
   Google Scholar
• De Souza ALR, Andreani T, Nunes FM, Cassimiro DL, de Almeida AE, Augusto CR, Vitorino Sarmento VH, Gremiao MPD, Silva AM, Souto EB. 2012. Loading of praziquantel in the crystal lattice of solid lipid nanoparticles: studies by DSC and SAXS. J Therm Anal Calorim. 108:353–360.
   Web of Science ®Google Scholar
• Derycke AS, Kamuhabwa A, Gijsens A, Roskams T, De Vos D, Kasran A, Huwyler J, Missiaen L, de Witte PA. 2004. Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells. J Nat Cancer Inst. 96:1620–1630.
   PubMed Web of Science ®Google Scholar
• Elbialy NS, Mady MM. 2015. Ehrlich tumor inhibition using doxorubicin containing liposomes. Saudi Pharm J: SPJ. 23:182–187.
   PubMed Web of Science ®Google Scholar
• Erdogar N, İskit AB, Eroglu H, Sargon MF, Mungan NA, Bilensoy E. 2014. Cationic core–shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy. Int J Pharm. 471:1–9.
   PubMedGoogle Scholar
• Estanqueiro M, Amaral MH, Conceição J, Sousa Lobo JM. 2015. Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids Surf B: Biointerf. 126:631–648.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Langer R. 2009. Impact of nanotechnology on drug delivery. ACS Nano. 3:16–20.
   PubMed Web of Science ®Google Scholar
• Fialho SL, Cunha Júnior AS. 2007. Drug delivery systems for the posterior segment of the eye: fundamental basis and applications. Arq Bras Oftalmol. 70:173–179.
   PubMedGoogle Scholar
• Frangos DN, Killion JJ, Fan D, Fishbeck R, von Eschenbach AC, Fidler IJ. 1990. The development of liposomes containing interferon alpha for the intravesical therapy of human superficial bladder cancer. J Urol. 6:1252–1256.
   Google Scholar
• Globocan. 2012. Cancer incidence and mortality worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr/Default.aspx
   Google Scholar
• Gonçalves C. 2014. Esquemas Terapêuticos no Carcinoma da Bexiga [dissertation]. Portugal (PT): Universidade Fernando Pessoa.
   Google Scholar
• González A, Tártara LI, Palma SD, Alvarez Igarzabal CI. 2015. Crosslinked soy protein films and their application as ophthalmic drug delivery system. Mater Sci Eng C Mater Biol Appl. 51:73–79.
   PubMed Web of Science ®Google Scholar
• Guhasarkar S, Banerjee R. 2010. Intravesical drug delivery: challenges, current status, opportunities and novel strategies. J Control Release. 148:147–159.
   PubMed Web of Science ®Google Scholar
• Guo H, Qian H, Idris NM, Zhang Y. 2010. Singlet oxygen-induced apoptosis of cancer cells using upconversion fluorescent nanoparticles as a carrier of photosensitizer. Nanomedicine: Nanotechnol Biol Med. 6:486–495.
   PubMed Web of Science ®Google Scholar
• Gupta P, Vermani K, Garg S. 2002. Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov Today. 7:569–579.
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Mukai S, Sawada S, Sasaki Y, Akiyoshi K. 2015. Nanogel tectonic porous gel loading biologics, nanocarriers, and cells for advanced scaffold. Biomaterials. 37:107–115.
   PubMed Web of Science ®Google Scholar
• Haupt M, Thommes M, Heidenreich A, Breitkreutz J. 2013. Lipid-based intravesical drug delivery systems with controlled release of trospium chloride for the urinary bladder. J Control Release. 170:161–166.
   PubMed Web of Science ®Google Scholar
• Horiguchi Y, Larchian WA, Kaplinsky R, Fair WR, Heston WDW. 2000. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther. 7:844–851.
   PubMed Web of Science ®Google Scholar
• Hsu J, King MR. 2012. Applications of nanotechnology in bladder cancer therapy. J Healthcar Eng. 3:535–550.
   Web of Science ®Google Scholar
• Huang Z, Li X, Zhang T, Song Y, She Z, Li J, Deng Y. 2014. Progress involving new techniques for liposome preparation. Asian J Pharm Sci. 9:176–182.
   Google Scholar
• Irache JM, Esparza I, Gamazo C, Agüeros M, Espuelas S. 2011. Nanomedicine: novel approaches in human and veterinary therapeutics. Vet Parasitol. 180:47–71.
   PubMed Web of Science ®Google Scholar
• Jahanshahi M, Babaei Z. 2008. Protein nanoparticle: a unique system as drug delivery vehicles. J Biotechnol. 7:4926–4934.
   Web of Science ®Google Scholar
• Jaiswal MK, Pradhan L, Vasavada S, De M, Sarma HD, Prakash A, Bahadur D, Dravid VP. 2015. Magneto-thermally responsive hydrogels for bladder cancer treatment: therapeutic efficacy and in vivo biodistribution. Colloids Surf B: Biointerf. 136:625–633.
   PubMed Web of Science ®Google Scholar
• Ji S, Liu C, Zhang B, Yang F, Xu J, Long J, Jin C, Fu D-L, Ni Q-X, Yu X-J, et al. 2010. Carbon nanotubes in cancer diagnosis and therapy. Biochim Biophys Acta. 1806:29–35.
   PubMed Web of Science ®Google Scholar
• Johnson JW, Nayar R, Killion JJ, von Eschenbach AC, Fidler IJ. 1989. Binding of liposomes to human bladder tumor epithelial cell lines: implications for an intravesical drug delivery system for the treatment of bladder cancer. Select Cancer Ther. 5:147–155.
   PubMedGoogle Scholar
• Karjiban RA, Basri M, Rahman MBA, Salleh AB. 2012. Structural properties of nonionic Tween80 micelle in water elucidated by molecular dynamics simulation. APCBEE Proc. 3:287–297.
   Google Scholar
• Kaufman DS, Shipley WU, Feldman AS. 2009. Bladder cancer. Lancet. 374:239–249.
   PubMed Web of Science ®Google Scholar
• Kiriluk KJ, Prasad SM, Patel AR, Steinberg GD, Smith ND. 2012. Bladder cancer risk from occupational and environmental exposures. Urol Oncol: Semin Orig Invest. 30:199–211.
   PubMed Web of Science ®Google Scholar
• Ko YJ, Canil CM, Mukherjee SD, Winquist E, Elser C, Eisen A, Reaume MN, Zhang L, Sridhar SS. 2013. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol. 14:769–776.
   PubMed Web of Science ®Google Scholar
• Kos MK, Bogataj M, Mrhar A. 2010. Mucoadhesion on urinary bladder mucosa: the influence of sodium, calcium, and magnesium ions. Pharmazie. 65:505–509.
   PubMed Web of Science ®Google Scholar
• Lastra OLV. 2006. Terapia gênica. Med Interna Mexico. 22:422–438.
   Google Scholar
• Le Visage C, Rioux-leclercq N, Haller M, Breton P, Malavaud B, Leong KAM. 2004. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer. J Urol. 171:1324–1329.
   PubMed Web of Science ®Google Scholar
• Lerner SP. 2005. Bladder cancer clinical trials. Urol Oncol J: Semin Orig Invest. 23:275–279.
   PubMed Web of Science ®Google Scholar
• Lestre SIA, Gameiro CD, João A, Lopes MJP. 2011. Granulomas of the penis: a rare complication of intravesical therapy with Bacillus Calmette-Guerin. An Bras Dermatol. 86:759–762.
   PubMed Web of Science ®Google Scholar
• Lin CC, Metters AT. 2006. Hydrogels in controlled release formulations: network design and mathematical modeling. Adv Drug Deliv Rev. 58:1379–1408.
   PubMed Web of Science ®Google Scholar
• Lin TY, Li YP, Zhang H, Luo J, Goodwin N, Gao T, White Rde V, Lam KS, Pan CX. 2014. Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer. Nanomedicine. 8:1239–1251.
   Web of Science ®Google Scholar
• Lin T, Wu J, Zhao X, Lian H, Yuan A, Tang X, Zhao S, Guo H, Hu Y. 2014. In situ floating hydrogel for intravesical delivery of adriamycin without blocking urinary tract. J Pharm Sci. 103:927–936.
   PubMed Web of Science ®Google Scholar
• Lin TY, Zhang H, Luo J, Li Y, Gao T, Lara PN Jr., White RV, Lam KS, Pan CX. 2012. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int J Nanomed. 7:2793–2804.
   PubMed Web of Science ®Google Scholar
• Linton KD, Rosario DJ, Thomas F, Rubin N, Goepel JR, Abbod MF, Catto JWF. 2012. Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance. J Urol. 189:828–833.
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB, Obek C, Soloway MS, Block NL. 1997. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res. 57:773–777.
   PubMed Web of Science ®Google Scholar
• Lopes RM, Corvo ML, Eleutério CV, Carvalheiro MC, Scoulica E, Cruz ME. 2012. Formulation of oryzalin (ORZ) liposomes: in vitro studies and in vivo fate. Eur J Pharm Biopharm. 82:281–290.
   PubMed Web of Science ®Google Scholar
• Lu S, Neoh K, Kang ET, Mahendran R, Chiong E. 2015. Mucoadhesive polyacrylamide nanogel as a potential hydrophobic drug carrier for intravesical bladder cancer therapy. Eur J Pharm Sci. 72:57–68.
   PubMed Web of Science ®Google Scholar
• Lu S, Neoh KG, Huang C, Shi Z, Kang ET. 2013. Polyacrylamide hybrid nanogels for targeted cancer chemotherapy via co-delivery of gold nanoparticles and MTX. J Colloid Interface Sci. 412:46–55.
   PubMed Web of Science ®Google Scholar
• Lu Z, Yeh T, Wang J, Chen L, Lyness G, Xin Y, Wientjes MG, Bergdall V, Couto G, Alvarez-Berger F, et al. 2011. Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy. J Urol. 185:1478–1483.
   PubMed Web of Science ®Google Scholar
• Ma Y, Hu Q, Luo W, Pratt RN, Glenn ST, Liu S, Trump DL, Johnson CS et al. 2015. 1α,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells. J Steroid Biochem Mol Biol. 148:166–171.
   PubMed Web of Science ®Google Scholar
• Malmström PU. 2003. Intravesical therapy of superficial bladder cancer. Crit Rev Oncol Hematol. 47:109–126.
   PubMed Web of Science ®Google Scholar
• Manyikana M, Choonara YE, Tomar LK, Tyagi C, Kumar P, du Toit LC, Pillay V. 2016. A review of formulation techniques that impact the disintegration and mechanical properties of oradispersible drug delivery technologies. Pharm Dev Technol. 21:354–366.
   PubMed Web of Science ®Google Scholar
• Martin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang K, Liu J, Wheeler MA, Kelly WK, Tew GN, Saltzman WM, et al. 2013. Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomed: Nanotechnol Biol. 9:1124–1134.
   PubMed Web of Science ®Google Scholar
• Mckiernan JM, Barlow LJ, Laudano MA, Mann MJ, Petrylak DP, Benson MC. 2011. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of Bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer. J Urol. 186:448–451.
   PubMed Web of Science ®Google Scholar
• McKiernan J, Chang S. 2013. Phase 1/2 study of ABI-009 in nonmuscle invasive bladder cancer. Available from: https://clinicaltrials.gov/show/NCT02009332
   Google Scholar
• Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. 2009. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 4:99–10.
   PubMed Web of Science ®Google Scholar
• Mohanraj VJ, Chen Y. 2007. Nanoparticles – a review. Trop J Pharm Res. 5:561–573.
   Google Scholar
• Mugabe C, Matsui Y, So AI, Gleave ME, Baker JH, Minchinton AI, Manisali I, Liggins R, Brooks DE, Burt HM. 2011. In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer. Clin Cancer Res. 17:2788–2799.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Fukiage M, Higuchi M, Nakaya A, Yano I, Miyazaki J, Nishiyama H, Akaza H, Ito T, Hosokawa H, Nakayama T, Harashima H. 2014. Nanoparticulation of BCG-CWS for application to bladder cancer therapy. J Control Release. 176:44–53.
   PubMed Web of Science ®Google Scholar
• Neutsch L, Plattner VE, Polster-Wildhofen S, Zidar A, Chott A, Borchard G, Zechner O, Gabor F, Wirth M. 2011. Lectin mediated biorecognition as a novel strategy for targeted delivery to bladder cancer. Investig Urol. 186:1481–1488.
   Google Scholar
• Neutsch L, Wirth E, Spijker S, Pichl C, Kählig H, Gabor F, Wirth M. 2013. Synergistic targeting/prodrug strategies for intravesical drug delivery – lectin-modified PLGA microparticles enhance cytotoxicity of stearoyl gemcitabine by contact-dependent transfer. J Colloids Interface Sci. 169:62–72.
   Google Scholar
• Nogueira L, Reis R, Machado R, Tobias-Machado M, Carvalhal G, Freitas Jr C, Magnabosco W, Menezes CL, Corradi C, Reis LO, et al. 2013. Cutaneous ureterostomy with definitive ureteral stent as urinary diversion option in unfit patients after radical cystectomy. Acta Cir Bras. 28:43–47.
   PubMed Web of Science ®Google Scholar
• Oliveira MB, Calixto G, Graminha M, Cerecetto H, González M, Chorilli M. 2015. Development, characterization, and in vitro biological performance of fluconazole-loaded microemulsions for the topical treatment of cutaneous leishmaniasis. BioMed Res Int. 2015:396894.
   PubMed Web of Science ®Google Scholar
• Oliveira V, Pereira MM, de Mello Brandão H, Brandão MAF, Gattaz WF, Raposo NRB. 2011. Nanotubos de carbono aplicados às neurociências: perspectivas e desafios. Rev psiquiatr clín. 38:201–206.
   Google Scholar
• Peppas N, Bures P, Leobandung W, Ichikawa H. 2000. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm. 50:27–46.
   PubMed Web of Science ®Google Scholar
• Pereira RRA, Bruschi ML. 2012. Vaginal mucoadhesive drug delivery systems. Drug Dev Ind Pharm. 38:643–652.
   PubMed Web of Science ®Google Scholar
• Pimentel LF, Jácome Júnior AT, Mosqueira VCF, Santos-Magalhães NS. 2007. Nanotecnologia farmacêutica aplicada ao tratamento da malária. Rev Bras Cienc Farm. 43:503–514.
   Google Scholar
• Pompeo ACL, Carrerette BF, Glina S, Ortiz V, Ferreira U, Coradi Fonseca CE. 2008. Cancro da bexiga – tratamento do carcinoma invasivo e metastático. Rev Assoc Med Bras 54:283–297.
   PubMedGoogle Scholar
• Qian HS, Guo HC, Ho PCL, Mahendran R, Zhang Y. 2009. Mesoporous-silica-coated up-conversion fluorescent nanoparticles for photodynamic therapy. Small. 5:2285–2290.
   PubMed Web of Science ®Google Scholar
• Rieger C, Kunhardt D, Kaufmann A, Schendel D, Huebner D, Erdmann K, Propping S, Wirth MP, Schwenzer B, Fuessel S, et al. 2015. Characterization of different carbon nanotubes for the development of a mucoadhesive drug delivery system for intravesical treatment of bladder cancer. Int J Pharm. 479:357–363.
   PubMedGoogle Scholar
• Rivera P, Orio M, Hinostroza J, Venegas P, Pastor P, Gorena M, Lagos M, Pinochet R. 1999. Our experience with 1 mg BCG vaccine instillation in T1 stage cancer of the bladder. Actas Erol Espanol. 23:757–762.
   PubMedGoogle Scholar
• Santos JC, Rolim N, Rodrigues T, Lopes F, Mota RL, Covita A, Soares MJ, Monteiro P, Canhoto A, Nogueira R, et al. 2014. Terapêutica intravesical com bacilo de Calmette-Guérin no tratamento do carcinoma da bexiga/o que sabemos até agora. Acta Urol Portuguesa. 31:75–81.
   Google Scholar
• Santos JFD. 2013. Caracterização do perfil genómico do Cancro da Bexiga – Contribuição para o desenvolvimento de uma metodologia de diagnóstico e monitorização molecular [dissertation]. Portugal (PT): Universidade de Coimbra.
   Google Scholar
• Schwendener RA. 2014. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines. 2:159–182.
   PubMedGoogle Scholar
• Severino P, Santana MHA, Malmonge SM, Souto EB. 2011. Polímeros usados como sistemas de transporte de princípios ativos. Polímeros. 21:361–368.
   Google Scholar
• Shaikh R, Raj Singh TR, Garland MJ, Woolfson AD, Donnelly RF. 2011. Mucoadhesive drug delivery systems. J Pharm Bioallied Sci. 3:89–100.
   PubMed Web of Science ®Google Scholar
• Silva C, Ribeiro A, Ferreira D, Veiga F. 2003. Administração oral de peptídeos e proteínas: II. Aplicação de métodos de microencapsulação. Braz J Pharm Sci. 39:1–20.
   Google Scholar
• Simplicio F, Maionchi F, Hioka N. 2002. Terapia fotodinâmica: aspectos farmacológicos, aplicações e avanços recentes no desenvolvimento de medicamentos. Quím Nova. 25:801–807.
   Web of Science ®Google Scholar
• Szlachcic A, Pala K, Zakrzewska M, Jakimowicz P, Wiedlocha A, Otlewski J. 2012. FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int J Nanomedicine. 7:5915–5927.
   PubMed Web of Science ®Google Scholar
• Tanagho E, Mcaninch J. 2014. Smith urologia geral. In: Smith urologia geral. Vol. 16a. Rio de Janeiro: Guanabara Koogan; p. 406–428.
   Google Scholar
• Tuomikoski L, Collan J, Keyriläinen J, Visapää H, Saarilahti K, Tenhunen M. 2011. Adaptive radiotherapy in muscle invasive urinary bladder cancer—an effective method to reduce the irradiated bowel volume. Radiother Oncol. 99:61–66.
   PubMed Web of Science ®Google Scholar
• Tyler A. 2012. Urothelial cancers: ureter, renal pelvis, and bladder. Semin Oncol Nurs. 28:154–162.
   PubMedGoogle Scholar
• Underwood C, van Eps A. 2012. Nanomedicine and veterinary science: the reality and the practicality. Vet J. 193:12–23.
   PubMed Web of Science ®Google Scholar
• Wei J, Cheang T, Tang B, Xia H, Xing Z, Chen Z, Fang Y, Chen W, Xu A, Wang S, et al. 2013. The inhibition of human bladder cancer growth by calcium carbonate/CaIP6 nanocomposite particles delivering AIB1 siRNA. Biomaterials. 34:1246–1254.
   PubMed Web of Science ®Google Scholar
• WHO. 2015. Cancer. Fact sheet No. 297. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/
   Google Scholar
• Winquist E, Ernst DS, Jonker D, Moore MJ, Segal R, Lockwood G, Rodgers A. 2003. Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract. Eur J Cancer. 39:1866–1871.
   PubMed Web of Science ®Google Scholar
• Yang C, Wang X, Yao X, Zhang Y, Wu W, Jiang X. 2015. Hyaluronic acid nanogels with enzyme-sensitive cross-linking group for drug delivery. J Control Release. 205:206–217.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Zhang Z, Yamashita K, Noda M. 2015. Biosensing of interaction between liposome of model cell membrane and amyloid-beta protein by dielectric dispersion analysis. Proc Eng. 120:560–563.
   Google Scholar
• Zhang D, Sun P, Li P, Xue A, Zhang X, Zhang H, Jin X. 2013. A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette-Guérin in the treatment of bladder cancer. Biomaterials. 34:10258–10266.
   PubMed Web of Science ®Google Scholar
• Zhou D, Zhang G, Gan Z. 2013. c(RGDfK) decorated micellar drug delivery system for intravesical instilled chemotherapy of superficial bladder cancer. J Control Rel. 169:204–210.
   PubMed Web of Science ®Google Scholar